CEO Jeff Andreson buys 10,000 shares of ICHR at $16.86; stock down 60.8% from 52-week high and trading near lows.
CEO Jeff Andreson purchased 10,000 shares at $16.86, raising his holdings to 285,594 shares (+3.6%). The purchase occurs after the stock has fallen 60.8% from its 52-week high of $42.70 and is trading near the lower bound of its 52-week range ($16.00–$42.70). Notably, ICHR is unprofitable (net income $-4.6M on $244.5M quarterly revenue) and has declined 48.4% over the last 90 days. Andreson's prior two sales at this ticker were both well-timed at the 90-day mark, with the stock falling after those transactions, suggesting a pattern of disciplined exit timing. This buy arrives at an absolute low in price and follows periods when he has previously exited at better levels, warranting investor attention to why he is initiating a fresh position at this valuation.
CEO Jeff Andreson sold 42.8K ICHR shares at $34.58 on 2024-11-25; stock now at $32.16, down 29.3% from 52-week high
CEO Jeff Andreson sold 42,800 shares at $34.58 on 2024-11-25, reducing his stake by 13.8%, in a company facing significant headwinds: annual revenue declined 36.6% year-over-year and net income was negative at $-2.8M. His cross-ticker track record shows prior sells that were well-timed 100% of the time with a 90-day average return of -21.1%, and his prior ICHR sale on 2024-05-24 similarly preceded a 21.1% decline over 90 days. The stock is now trading at $32.16, down 29.3% from its 52-week high of $45.48, suggesting the timing pattern has continued. However, the 30-day momentum is positive at +15.5%, indicating a recent recovery phase despite ongoing operational challenges.
